《新股》維立志博(09887.HK)今起招股入場費3,535.3元 引騰訊(00700.HK)為基投
生物科技公司維立志博-B(09887.HK)公布在港招股詳情,計劃全球發售3,205.44萬股H股,其中國際配售佔90%或約2,884.89萬股,香港公開發售佔10%或約320.55萬股,發售價介乎每股31.6至35元,每手100股入場費約3,535.3元。
維立志博今日(17日)起至下周二(22日)招股,預計下周五(25日)在聯交所掛牌上市,由摩根士丹利及中信証券擔任聯席保薦人。本次IPO引入10名基石投資者,包括正心谷資本、OrbiMed、高毅實體、Perseverance Asset Management、TruMed Healthcare Master Fund、騰訊(00700.HK)、易方達基金、Foresight Funds、Sage Partners及漢康實體。基投將合共認購約6,900萬美元等值股份,以發售價中位數33.3元計,將涉及1,626.45萬股。
按發售價中位數計,公司預計集資淨額約9.68億元,預料當中約65%將用於臨床階段候選藥物的開發及監管事務,約15%用於推進臨床前資產及優化技術平台,約10%用於提升生產能力及商業化準備,剩餘約10%將用作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.